Synthesis and anti-tubercular and antimicrobial activities of some 2r,4c-diaryl-3-azabicyclo[3.3.1]nonan-9-one N-isonicotinoylhydrazone derivatives

European Journal of Medicinal Chemistry

Volumn 45, Issue 11, 2010, Pages 5480-5485

  Sankar, C ^a   Pandiarajan, K ^a  

^a ANNAMALAI UNIVERSITY   (India)

Author keywords

3 Azabicyclo 3.3.1 nonane; Antimicrobial activity; Antituberculosis activity; Isoniazid; Mycobacterium tuberculosis

Indexed keywords

2R,4C BIS(3 CHLOROPHENYL) 3 AZABICYCLO[3.3.1]NONAN 9 ONE N ISONICOTINOYLHYDRAZONE; 2R,4C BIS(3 METHOXYPHENYL) 3 AZABICYCLO[3.3.1]NONAN 9 ONE N ISONICOTINOYLHYDRAZONE; 2R,4C BIS(4 CHLOROPHENYL) 3 AZABICYCLO[3.3.1]NONAN 9 ONE N ISONICOTINOYLHYDRAZONE; 2R,4C BIS(4 FLUOROPHENYL) 3 AZABICYCLO[3.3.1]NONAN 9 ONE N ISONICOTINOYLHYDRAZONE; 2R,4C BIS(4 METHOXYPHENYL) 3 AZABICYCLO[3.3.1]NONAN 9 ONE N ISONICOTINOYLHYDRAZONE; 2R,4C BIS(4 METHYLPHENYL) 3 AZABICYCLO[3.3.1]NONAN 9 ONE N ISONICOTINOYLHYDRAZONE; 2R,4C DIPHENYL 3 AZABICYCLO[3.3.1] NONAN 9 ONE; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ISONIAZID; LUCIFERASE; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS NIGER; BACILLUS SUBTILIS; CANDIDA ALBICANS; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ESCHERICHIA COLI; HYDROGEN BOND; IN VITRO STUDY; INFRARED SPECTROSCOPY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STEREOCHEMISTRY;

ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; BACTERIA; FUNGI; HYDRAZONES; MAGNETIC RESONANCE SPECTROSCOPY; MICROBIAL SENSITIVITY TESTS; SPECTROPHOTOMETRY, INFRARED;

EID: 77957845753     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.08.024     Document Type: Article

References (24)

1. P.G. Smith, and A.R. Moss Epidemiology of Tuberculosis B.R. Bloom, Tuberculosis 1994 ASM Press Washington, D.C. 47 59
2. World Health Organization Tuberculosis Programme Available from: http://www.who.int/tb/en/June 2009
3. T.S. Cole, W. Phillip, and B. Heym Mechanisms of drug resistance in Mycobacterium tuberculosis Curr. Top. Microbiol. 215 1996 49 69 (Pubitemid 26270591)
4. E.C. Rivers, and R.L. Mancera New anti-tuberculosis drugs in clinical trials with novel mechanisms of action Drug. Discov. Today. 13 2008 1090 1098
5. R. Johnson, E.M. Streicher, G.E. Louw, R.M. Warren, P.D. Van Helden, and T.C. Victo Drug resistance in Mycobacterium tuberculosis Curr. Issues. Mol. Biol. 8 2006 97 112
6. R.J. O'Brien, and P.P. Nunn The need for new drugs against tuberculosis: obstacles, opportunities, and next steps Am. J. Respir. Crit. Care Med 163 2001 1055 1058
7. C. Crabb Global alliance at full steam for new TB drugs Bull. World. Health. Organ. 80 2002 517
8. R. Maccari, R. Ottaná, and M.G. Vigorita In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14 Bioorg. Med. Chem. Lett. 15 2005 2509 2513
9. D. Sriram, P. Yogeeswari, and K. Madhu Synthesis and in vitro and in vivo antimycobacterial activity of isonicotinoyl hydrazones Bioorg. Med. Chem. Lett. 15 2005 4502 4505
10. N. Sinha, S. Jain, A. Tilekar, R.S. Upadhayaya, N. Kishore, G.H. Jana, and S.K. Arora Synthesis of isonicotinic acid N′-arylidene-N-[2-oxo-2-(4- aryl-piperazin-1-yl)-ethyl]-hydrazides as antituberculosis agents Bioorg. Med. Chem. Lett. 15 2005 1573 1576
11. M.J. Hearn, and M.H. Cynamon Design and synthesis of antituberculars: preparation and evaluation against Mycobacterium tuberculosis of an isoniazid Schiff base J. Antimicrob. Chemother. 53 2004 185 191
12. M.J. Hearn, M.H. Cynamon, M.F. Chen, R. Coppins, J. Davis, H. Joo-On Kang, A. Noble, B. Tu-Sekine, M.S. Terrot, D. Trombino, M. Thai, E.R. Webster, and R. Wilson Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid Eur. J. Med. Chem. 44 2009 4169 4178
13. D. Barker, D.H.-S. Lin, J.E. Carland, C.P.-Y. Chu, M. Chebib, M.A. Brimble, G.P. Savage, and M.D. Mc. Leod Methyllycaconitine analogues have mixed antagonist effects at nicotinic acetylcholine receptors Bioorg. Med. Chem. 13 2005 4565 4575
14. R. Jeyaraman, and S. Avila Chemistry of 3-azabicyclo[3.3.1]nonanes Chem. Rev. 81 1981 149 174
15. S. Chitra, D. Devanathan, and K. Pandiarajan Synthesis and in vitro microbiological evaluation of novel 4-aryl-5-isopropoxycarbonyl-6-methyl-3,4- dihydropyrimidinones Eur. J. Med. Chem. 45 2010 367 371
16. P.M. Sivakumar, S. Prabu seenivasan, Vanaja Kumar, and Mukesh Doble Synthesis, antimycobacterial activity evaluation, and QSAR studies of chalcone derivatives Bioorg. Med. Chem. Lett. 17 2007 1695 1700
17. Z.K. Khan. In vitro and vivo screening technique for bioactivity screening and evaluation. In: Proc. Int. Workshop UNIDO-CDRI; 1997. p. 210-1.
18. R.S. Varma, Antifungal Agents: Present and Future Prospects 1998 National Academy of Chemistry & Biology Lucknow, India
19. R.M. Silverstein, and F.X. Webster Spectrometric Identification of Organic Compounds sixth ed 1998 Wiley New York 209
20. R.M. Silverstein, and F.X. Webster Spectrometric Identification of Organic Compounds sixth ed 1998 Wiley New York 229
21. Yu.P. Gladii, T.T. Omarov, and M.Zh. Buranbaev X-ray diffraction study of 2,4-diphenyl-9-ethynyl-3-azabicyclo-[3.3.1]nonan-9-ol J. Struct. Chem. 34 2 1993 179 181
22. R. Le Gall, C. Marchand, and J. Rees Impacts of antibiotics on in vitro UVA-susceptibility of human skin fibroblasts Eur. J. Dermatol. 15 3 2005 146 151
23. P. Ruiz, F. Rodriguez-Cano, F.J. Zerolo, and M. Casal Investigation of the in vitro activity of streptomycin against Mycobacterium tuberculosis Microb. Drug. Resist. 8 2 2002 147 149
24. V. Baliah, and R. Jeyaraman Synthesis of some 3-azabicyclo[3.3.1]nonan-9- one Indian. J. Chem. 9 1971 1020 1022